Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine.

The efficacy and tolerability of risperidone long-acting injectable were investigated in patients with schizophrenia or other psychotic disorders who had previously been symptomatically stable on olanzapine treatment. Patients received risperidone long-acting injectable, 25 mg, by intramuscular injection every 2 weeks; the dose could be increased to 37.5 or 50 mg if necessary. Patients were transferred directly from their previous medication to risperidone long-acting injectable without a run-in period of oral risperidone treatment. Of 192 patients recruited, 134 patients (70%) completed the study. The principal reasons for discontinuation were withdrawal of consent (8%), adverse events (6%), insufficient response (5%) and non-compliance (4%). Risperidone long-acting injectable produced a significant improvement (p = 0.0001) in Positive and Negative Syndrome Scale (PANSS) total scores, from 74.2+/-21.3 at baseline to 65.8+/-21.4 at endpoint. There were also significant reductions in PANSS subscales (positive symptoms, negative symptoms, general psycho-pharmacology) and Marder factor scores. The Clinical Global Impression increased significantly from baseline to endpoint (p = 0.0001), as reflected by the increase in the proportion of patients rated as 'not ill' or 'borderline ill' from 10% at baseline to 21% at endpoint. Risperidone long-acting injectable was also associated with significant improvements in Global Assessment of Function, patient satisfaction with treatment, and quality of life, measured on the SF-36 scale. Movement disorders, measured on the Extrapyramidal Symptom Rating Scale, were significantly reduced following the change to risperidone long-acting injectable. Treatment with risperidone long-acting injectable was well tolerated, and no significant weight gain occurred during the study. This open study suggests that risperidone long-acting injectable produces symptomatic improvement in schizophrenia patients previously considered symptomatically stable with olanzapine, along with improvement in movement disorders. The combination of improved efficacy and good tolerability may have important implications for patient adherence to therapy and subsequent long-term outcomes.

Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.

The efficacy and safety of risperidone long-acting injectable (RLAI) was investigated in patients in the early phases of schizophrenia and schizoaffective disorders (< or = 3 years). Patients who required a treatment change received RLAI (2-weekly gluteal injections of 25, 37.5 or 50 mg, per clinical judgement), without an oral risperidone run-in phase.A total of 382 patients were included in this 6-month open-label study; 73% of patients completed the study. A total of 84% had schizophrenia with a median duration of 1.0 year since diagnosis. Previous medications were mainly atypical antipsychotics (70%) and depot neuroleptics (24%). The main reasons for treatment change were non-compliance (42%) and insufficient efficacy (31%) of previous medication. The total Positive and Negative Syndrome Scale (PANSS) and all its subscale scores improved significantly (p < or = 0.0001), with 40% of patients showing a 20% improvement on total PANSS. Global Assessment of Functioning, quality of life, patient satisfaction and movement disorders also improved significantly. Tolerability of RLAI was generally good and no unexpected adverse events were reported. The ensured delivery of medication with RLAI resulted in significant symptom improvement in this patient population. Direct initiation of RLAI is well accepted by patients. RLAI might represent a novel option for patients in the early phases of psychosis.

Cytotoxic effect of fatty acids in vitro on Ehrlich exudative carcinoma cells and normal exudative cells (leukocytes).

A mixture of pure fatty acids isolated hydrolytically from linseed oil in the form of water-soluble salts with ethanolamine were examined for cytotoxicity for Ehrlich carcinoma and normal exudative cells. Cytotoxicity of the mixture was similar to that of salts of oleic and linolenic acids. On the other hand, the mixture of fatty acids and oleic acids was more toxic for normal exudative cells than linolenic acid.

[Placental lactogen level and activity of oxytocinase, beta-glucuronidase and thermostable alkaline phosphatase isoenzyme in blood serum of women with ectopic pregnancy]. / Poziom laktogenu lozyskowego oraz aktywnosc oksytocynazy, beta-glukuronidazy i termostabilnego izoenzymu fosfatazy alkalicznej w surowicy krwi kobiet z ciaza ektopowa.

The lack of literature data dealing with placental lactogen concentration as well as with the other biochemical parameters in blood serum in women with ectopic pregnancy was the reason we turned to that problem. In eight patients with ectopic pregnancy there was determined placental lactogen level and oxytocinase activity as well as the activity of beta-glucuronidase and thermostable alkali phosphatase isoenzyme in blood serum. The results obtained were compared to the concentration of those parameters in blood serum in women with ectopic pregnancy and to those of not pregnant women. It was stated that in women with ectopic pregnancy there was produced placental lactogen and its concentration in blood serum was lower (about 30 percent) than that in women with ectopic pregnancy. Similarly, mean value of oxytocinase activity in women with ectopic pregnancy was twice lower in comparison to that of ectopic pregnancy, while beta-glucuronidase activity was twice higher when compared to that of ectopic pregnancy values. Placental alkali phosphatase isoenzyme activity was similar in both groups of pregnant women.

[Comparative research on some clinical and psychopharmacological parameters of reactive paranoid psychoses]. / Badania porównawcze niektórych parametrów klinicznych i psychofarmakologicznych psychoz paranoidalnych reaktywnych.

10 patients suffering from reactive psychoses were treated in a standardized manner with pernazine. The dynamic of the clinical picture as well as the behaviour of prolactin levels and the activity of DBH in blood plasma were assessed.

[Comparative studies of various clinical and psychopharmacological parameters of schizoaffective psychosis and paranoid schizophrenia]. / Badania porównawcze niektórych parametrów klinicznych i psychofarmakologicznych psychozy schizoafektwnej i schizofrenii paranoidalnej.

Two groups of male patients were investigated: 19 subjects with diagnosis of paranoid schizophrenia and 13 with schizoaffective psychosis (8 with both depressive and paranoid symptoms, 5 with manic and paranoid). All patients were treated with perazine in this same manner. During the consecutive stages of therapy the following parameters were examined and compared: clinical symptoms, DBH activity, plasma prolactin concentration and the simple reaction time task to auditory and visual stimuli. The noticeable changes, similarities and differences were described.

[Prognostic value of measuring serum angiotensin I-converting enzyme (ACE) in patients with sarcoidosis]. / Prognostyczna wartosc oznaczania enzymu konwertujacego angiotensyne I (ACE) w surowicy chorych na sarkoidoze.

Serum ACE (s-ACE) activity were determined in 112 sarcoid patients and 60 healthy volunteers. The mean s-ACE activity in sarcoid patients were 39.5 +/- 14.1 U. and in healthy volunteers 22.1 +/- 3.6, U. Significant increase of s-ACE was seen in active sarcoidosis 51.2 +/- 13.7 U. Serum ACE activity increased twice or more in comparison with control values imply activity of the process. Serum-ACE determination may be of use as a prognostic factor in sarcoidosis.